IP Library › Granted Patent US 11,408,009
Granted Patent B2
US 11,408,009 · App. 16/224,257 · Granted Aug 9, 2022

Host cell expression of 4-hydroxyphenylacetaldehyde synthase for production of salidroside, icariside D2, and precursors

Inventors: Michael Torrens-Spence (Cambridge, MA); Jing-Ke Weng (Belmont, MA)
Assignee: Whitehead Institute for Biomedical Research
C12N15/8257C12N15/52C12N15/70C12N15/743C12N15/81C12N15/8243C12N15/8245C12P17/06C12Y114/13068C12Y204/0117C12Y401/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,408,009
App. No.
16/224,257
Granted
Aug 9, 2022
Kind
B2
Abstract

Transgenic host cells, vectors useful for making transgenic host cells, and kits useful for making transgenic host cells are described. Also described are transgenic plants. In some embodiments, transgenic host cells express a 4-hydroxyphenylacetaldehyde synthase (4HPAAS). In some embodiments, transgenic host cells express a tyrosol:UDP-glucose 8-O-glucosyltransferase (T8GT). The transgenic host cells are useful for biosynthesis of one or more of salidroside, icariside D2, tyrosol, and 4-hydroxypenylacetaldehyde.

Claims (26)

1. A host cell comprising a transgene encoding a heterologous 4-hydroxyphenylacetaldehyde synthase (4HPAAS) operably linked to a promoter, wherein the heterologous 4HPAAS comprises an amino acid sequence having at least 95% amino acid sequence identity to SEQ ID NO: 2, and wherein the amino acid sequence of the heterologous 4HPAAS comprises:

a) an amino acid residue selected from the group consisting of L, I, M and V at a position corresponding to the F residue at position 343 in SEQ ID NO: 2;

b) an amino acid residue selected from the group consisting of N and D at a position corresponding to the H residue at position 198 in SEQ ID NO: 2; or

c) a combination thereof.

2. The host cell of claim 1 , wherein the amino acid sequence of the heterologous 4HPAAS comprises an amino acid residue selected from the group consisting of L, I, M and V at a position corresponding to the F residue at position 343 in SEQ ID NO: 2.

3. The host cell of claim 1 , wherein the amino acid sequence of the heterologous 4HPAAS comprises an amino acid residue selected from the group consisting of N and D at a position corresponding to the H residue at position 198 in SEQ ID NO: 2.

4. A host cell comprising a transgene encoding a heterologous 4-hydroxyphenylacetaldehyde synthase (4HPAAS) operably linked to a promoter, wherein the heterologous 4HPAAS comprises an amino acid sequence having at least 95% amino acid sequence identity to SEQ ID NO: 2, and wherein the amino acid sequence of the heterologous 4HPAAS comprises an amino acid residue selected from the group consisting of F, L, I, M and V at a position corresponding to the F residue at position 343 in SEQ ID NO: 2, and an amino acid residue selected from the group consisting of N and D at a position corresponding to the H residue at position 198 in SEQ ID NO: 2.

5. The host cell of claim 1 , wherein the host cell further comprises a transgene encoding a heterologous tyrosol:UDP-glucose 8-O-glucosyltransferase (T8GT) operably linked to a promoter, wherein the T8GT comprises an amino acid sequence having at least 95% identity to one or more of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, and SEQ ID NO: 20.

6. A method of making 4-hydroxyphenylacetaldehyde (4-HPAA) in a host cell, the method comprising expressing in the host cell a transgene that encodes a heterologous 4-hydroxyphenylacetaldehyde synthase (4HPAAS) operably linked to a promoter, wherein the heterologous 4HPAAS comprises an amino acid sequence having at least 95% amino acid sequence identity to SEQ ID NO: 2, and wherein the amino acid sequence of the heterologous 4HPAAS comprises:

a) an amino acid residue selected from the group consisting of L, I, M and V at a position corresponding to the F residue at position 343 in SEQ ID NO: 2;

b) an amino acid residue selected from the group consisting of N and D at a position corresponding to the H residue at position 198 in SEQ ID NO: 2; or

c) a combination thereof.

7. The method of claim 6 , wherein the amino acid sequence of the heterologous 4HPAAS comprises an amino acid residue selected from the group consisting of L, I, M and V at a position corresponding to the F residue at position 343 in SEQ ID NO: 2.

8. The method of claim 6 , wherein the amino acid sequence of the heterologous 4HPAAS comprises an amino acid residue selected from the group consisting of N and D at a position corresponding to the H residue at position 198 in SEQ ID NO: 2.

9. A method of making 4-hydroxyphenylacetaldehyde (4-HPAA) in a host cell, the method comprising expressing in the host cell a transgene that encodes a heterologous 4-hydroxyphenylacetaldehyde synthase (4HPAAS) operably linked to a promoter, wherein the heterologous 4HPAAS comprises an amino acid sequence having at least 95% amino acid sequence identity to SEQ ID NO: 2, and wherein the amino acid sequence of the heterologous 4HPAAS comprises an amino acid residue selected from the group consisting of F, L, I, M and V at a position corresponding to the F residue at position 343 in SEQ ID NO: 2, and an amino acid residue selected from the group consisting of N and D at a position corresponding to the H residue at position 198 in SEQ ID NO: 2.

10. The method of claim 6 , wherein the amino acid sequence of the heterologous 4HPAAS comprises SEQ ID NO: 2.

11. The method of claim 6 , further comprising making tyrosol in the host cell, wherein the host cell further expresses a transgene encoding a heterologous 4-hydroxyphenylacetaldehyde reductase (4HPAR), wherein the heterologous 4HPAR comprises an amino acid sequence having SEQ ID NO: 4.

12. The method of claim 11 , further comprising making salidroside in the host cell, wherein the host cell further comprises one or more enzymes that catalyze conversion of tyrosol to tyrosol 8-O-glucoside (salidroside).

13. The method of claim 11 , further comprising making icariside D2 in the host cell, wherein the host cell further comprises one or more enzymes that catalyze conversion of tyrosol to icariside D2.

14. The host cell of claim 1 , wherein the host cell is a fungal cell or a bacterial cell.

15. The host cell of claim 14 , wherein the host cell is a fungal cell.

16. The host cell of claim 15 , wherein the fungal cell is a yeast cell.

17. The host cell of claim 16 , wherein the yeast cell is a Saccharomyces cerevisiae cell.

18. The host cell of claim 14 , wherein the host cell is a bacterial cell.

19. The host cell of claim 18 , wherein the bacterial cell is an Escherichia coli cell.

20. The host cell of claim 18 , wherein the bacterial cell is an Agrobacterium tumefaciens cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2019
From: TORRENS-SPENCE, MICHAEL; WENG, JING-KE
To: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
Reel/Frame 049347/0190 →
Continuity (2)
Provisional Application 62607271 · Dec 18, 2017
Related Publication 20190264221A1 · Aug 29, 2019
Cited By (1)
US 12,385,055